CytoSorbents Corporation, a critical care immunotherapy leader commercializing its CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, said Jan. 11 it appointed James Komsa as vice president U.S. sales and marketing, effective immediately.
Over a distinguished 18 year career at Medtronic, Komsa was most recently vice president of the Restorative Therapy Group (RTG) and the U.S. Pain Organization, with annual sales of $400 million and $1.1 billion, respectively, at the time. There, he was responsible for 16 business units, including Medtronic Spine, Neurology, ENT, Pain and others. Prior to that, Komsa led the successful turnaround of Kyphon as U.S. Vice President Medtronic Spine Division. Formerly as Vice President, Northeast Region, Medtronic Cardiac and Vascular Group (CVG), Komsa was responsible for sales, marketing and operations for the Coronary, Structural Heart, Endovascular, and Cardiac Rhythm Disease Management business units, encompassing more than 300 full-time employees and generating more than $310 million in annual sales.
Prior to his career at Medtronic, Komsa was Vice President at Hambrecht & Quist, where he helped lead the operations and rapid sales growth of two start-up companies, Paceart and Zymed, which were ultimately acquired by Medtronic and Philips, respectively. Most recently, Komsa was executive vice president and general manager of privately-held Pathy Medical, a medical device company focused on improving surgical illumination.
“It will be great to work with Jim in his role as VP of U.S. Sales and Marketing. Jim brings a wealth of cardiac medical device experience and best-of-class sales practices from his long tenure with Medtronic where he led sales teams in the cardiac surgery, pacing, spine, and neuromod divisions. His outstanding track record of building and managing high performing sales teams is expected to be the key to the success of our commercialization efforts here in the U.S. We plan to take advantage of our extensive history of selling CytoSorb in 67 countries worldwide to facilitate this process,” said Vincent Capponi, president and chief operating officer of CytoSorbents in a prepared statement.